1. Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer
- Author
-
Kunihiko Kobayashi, Takahiro Uchida, Yu Miura, Kyoichi Kaira, Yoshitake Murayama, Atsuto Mouri, Ou Yamaguchi, Ayako Shiono, Fuyumi Nishihara, Kosuke Hashimoto, and Hiroshi Kagamu
- Subjects
0301 basic medicine ,Male ,Lung Neoplasms ,Afatinib ,Gastroenterology ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Osimertinib ,EGFR‐TKI ,Aged, 80 and over ,Aniline Compounds ,biology ,Kinase ,Incidence (epidemiology) ,Incidence ,Interstitial lung disease ,General Medicine ,respiratory system ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,osimertinib ,Female ,Original Article ,Nivolumab ,Antibody ,medicine.drug ,Pulmonary and Respiratory Medicine ,Adult ,medicine.medical_specialty ,lcsh:RC254-282 ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Lung cancer ,Protein Kinase Inhibitors ,Aged ,Retrospective Studies ,nivolumab ,Acrylamides ,business.industry ,Original Articles ,medicine.disease ,respiratory tract diseases ,030104 developmental biology ,biology.protein ,business ,Lung Diseases, Interstitial ,ILD - Abstract
Background The aim of our study was to retrospectively assess the incidence of interstitial lung disease (ILD) related to EGFR-tyrosine kinase inhibitor (TKI) treatment immediately before and/or after the administration of a PD-1 antibody. Methods We analyzed the data of 26 patients who underwent treatment with EGFR-TKIs immediately before and/or after the administration of an anti-PD-1 antibody. Results Four out of the 26 patients developed ILD during EGFR-TKI treatment: three patients during the administration of osimertinib immediately after, and one during afatinib immediately before treatment with an anti-PD-1 antibody. Three of 12 patients who underwent EGFR-TKI therapy immediately after anti-PD-1 antibody treatment experienced osimertinib-induced ILD. ILD was not observed in the five patients administered an anti-PD-1 antibody followed by first or second-generation EGFR-TKIs. Conclusion ILD was observed in the treatment sequence of an anti-PD-1 antibody followed by osimertinib, but not with first or second-generation EGFR-TKIs. more...
- Published
- 2019